Remidio is the world's first integrated Ophthalmic hardware and Artificial Intelligence company headquartered in Bangalore, India, with subsidiaries in Singapore and the US. Remidio’s devices are used in more than 15 countries and have impacted more than 7.5M globally.
Remidio enables disruptive vision screening models using simple to use devices, with integrated "offline" AI on-the-edge, to screen for Cataract, Diabetic Retinopathy (DR), Glaucoma and uncorrected refractive errors, that affect more than 2 billlion globally.
Remidio uses principles of Design Thinking and involves key stakeholders during the product development process – clinicians, patients, technicians and health workers, with a view to designing product solutions that are simple to use, reliable & scalable. This way, we seek to impact the USD 5B, Ophthalmology and vision screening market with patented technologies that allow for high quality vision screening to be done in close to patient contexts such as a patient’s home, primary care centres, health fairs, as well as optometry and ophthalmology clinics. Innovation, customer interactions, feedback evaluations and subsequent upgradations help us stay relevant to the industry with time.
Upon completion of his Masters, PhD and post-doctoral work at MIT, Dr. Anand moved back to India to learn and experience first-hand, issues that impact access and affordability in the healthcare sector in the Indian context. Anand believes that in order to favourably impact the economics of delivery of healthcare solutions - innovations in chemistry, biology and engineering need to be combined with new business models that challenge currently existing paradigms. He also believes that constraints posed by a developing nation context - be it with respect to infrastructure, skilled human resources, need for extreme affordability in product costing - are an opportunity to innovate, resulting in scalable solutions that will be extremely relevant even in the first world context.
